Contact Us
菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn mailbox sharing button wuxivaccines@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Viral Vector Vaccines

Viral Vaccines Process Development

Leveraging WuXi Biologics’ HEK 293 Cells for Optimal Performance

 

Viral Vaccine Cell Culture Process Development

 

  • Multiple cell culture modes

 

    • Batch, fed-batch or perfusion

     

  • Flexible cell culture format 

 

    • Adherent cell culture (Cell Factory / cellSTAK, iCellis fixed-bed bioreactor) and microcarrier-based adherent cell culture
    • Suspension cell culture (Bioreactor)

     

  • Commercial media and chemically defined media preferred

Virus Purification Process Development

 

  • Early stage feasibility study
  • Process development towards IND filing
  • Late stage process geared-characterization

 

Innovations To Increase Virus Titer

Suspension Cell Culture
  • Intensified cell culture process using perfusion (ATF-based), to increase  cell density  2–5 fold
  • N-1 perfusion in wave system to reduce total cell expansion and overall production timelines
  • Cell culture scaling-up from bench scale to 200 L, and up to 2,000 L 
Adherent Cell Culture
  • Perfusion-based microcarrier cell culture in single-use bioreactors increase titers efficiently than a typical cell factory
  • Fixed-bed bioreactor, (e.g., iCellis), to greatly increase volumetric titer
Notice:

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?

Yes, continue to proceed
No, stay on this Website